SDZZ Stock Overview
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sandoz Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 32.32 |
| 52 Week High | CHF 33.13 |
| 52 Week Low | CHF 23.43 |
| Beta | 0 |
| 11 Month Change | 0.47% |
| 3 Month Change | 20.98% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| SDZZ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.8% | 0.5% | 0.6% |
| 1Y | n/a | 12.7% | 8.3% |
Return vs Industry: Insufficient data to determine how SDZZ performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SDZZ performed against the UK Market.
Price Volatility
| SDZZ volatility | |
|---|---|
| SDZZ Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SDZZ has not had significant price volatility in the past 3 months.
Volatility Over Time: SDZZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 22,633 | Richard Saynor | www.sandoz.com |
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.
Sandoz Group AG Fundamentals Summary
| SDZZ fundamental statistics | |
|---|---|
| Market cap | CHF 13.87b |
| Earnings (TTM) | CHF 68.88m |
| Revenue (TTM) | CHF 8.93b |
201.4x
P/E Ratio1.6x
P/S RatioIs SDZZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDZZ income statement (TTM) | |
|---|---|
| Revenue | US$9.98b |
| Cost of Revenue | US$5.42b |
| Gross Profit | US$4.56b |
| Other Expenses | US$4.49b |
| Earnings | US$77.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 45.74% |
| Net Profit Margin | 0.77% |
| Debt/Equity Ratio | 49.2% |
How did SDZZ perform over the long term?
See historical performance and comparison